AveXis

Jun 19, 2020

Global Spinal Muscular Atrophy Market Outlook to 2027 - Advent of Oral mRNA Splicer for Treatment

Aug 06, 2019

Statement by Peter Marks, M.D., Ph.D., director of FDA's Center for Biologics Evaluation and Research, on data accuracy issues with recently approved gene therapy

Jul 16, 2019

Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy

May 24, 2019

MDA Celebrates FDA Approval of Zolgensma for Treatment of Spinal Muscular Atrophy in Pediatric Patients

May 24, 2019

AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families

May 24, 2019

REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform

May 24, 2019

AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

May 24, 2019

FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality

May 07, 2019

New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1

May 05, 2019

AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

Nov 05, 2018

SAVSU Technologies to Supply evo® Cold Chain Technologies to AveXis